2012•The Journal of Clinical PsychiatryRequires access
Paroxetine combined risperidone in the treatment of negative symptoms of chronic schizophrenia patients
Zhao Chang-yi
Open publisher page 0 citations
Abstract
Objective:To evaluate clinical efficacy and safety of paroxetine combined risperidone in the treatment of negative symptoms of chronic schizophrenia patients.Method:126 patients with predominantly negative symptoms of chronic schizophrenia were randomly divided into study group (paroxetine combined risperidone) and the control group (risperidone alone) with 12 weeks' treatment.PANSS and TESS were used to assess the efficacy and safety respectively.Results:compared with before treatment,PANSS scores decreased significantly after treatment (P0.05).The scores on b1unted affect,emotional withdrawal,poor rapport and passive/apathetic social withdrawal were lower in the study group than in the control group at week 4,8 and 12,the score difference was statistically significant (P0.05 or P0.01).The adverse events of two groups were mild or moderate.Conclusion:Paroxetine combined risperidone in the treatment of chronic schizophrenia with negative symptoms showed rapid response,better efficacy and good patient compliance.